Introduction
FLBZ and ABZ orally administered as a CDs-solution to mice infected with E. granulosus. 98
Experimental designmedium (12). Viable and free PSC (1500 per Leighton tube) were incubated with 10 nmol/mL of FLBZ, R-126 FLBZ, ABZ or ABZSO. PSC incubated with culture medium alone or culture medium supplemented with 127 methanol was used as controls. Culture tubes were followed microscopically everyday. Samples of PSC 128 (approximately 70-90 PSC in 180 µL of incubation medium) from both control and treated groups were taken 129 every 6 days for up to 54 days. Vitality of the PSC was monitored using the methylene blue exclusion 130 technique. Additionally, ultrastructure studies with scanning electron microscopy (SEM) were performed. 131
Samples were fixed with 2.5% glutaraldehyde in sodium cacodylate buffer for 48 h at 4° C. Then, several 132 washes in cacodylate buffer were made. The specimens were dehydrated by sequential incubations in increasing 133 concentrations of ethanol and were finally immersed in hexamethyl-disilazane for 5 min, 1 h and then 134 overnight. They were then sputter-coated with gold (100 Å thick) and inspected on a JEOL JSM-6460 LV 135 (Peabody, MA, USA) scanning electron microscope operating at 15 kV. Plasma (100 µL) and cysts (0.5 g) samples were spiked with OBZ as internal standard (1 µg/mL). After 5 min, 159 plasma and cyst samples were supplemented with 1.5 mL of acetonitrile HPLC grade. Later samples were 160 shaked 15 min in multi-tube-vortexer (VWR, Scientifics Products, West Chester, PA, USA) and centrifuged at 161 3800 x g for 10 min. The supernatant was concentrated to dryness in a vacuum concentrator (Speed-Vac neither in plasma nor in cysts. ABZSO and ABZSO 2 were the main metabolites recovered in plasma. Similarly, 237 both metabolites were measured in cysts recovered from ABZ-treated mice. Higher peak plasma concentrations 238 (Cmax) were observed for ABZSO (2.60 ± 0.5 µg/mL) compared to ABZSO 2 (0.40 ± 0.1 µg/mL). A similar 239 pattern was observed in cysts, where ABZSO concentrations were 5-fold higher than those observed for 240 ABZSO 2 . These results were reflected in a higher AUC value for ABZSO both in plasma (4.40 ± 0.4 µg.h/mL) 241 and cysts (1.50 ± 0.1 µg.h/g) compared to those obtained for ABZSO 2 (0.70 ± 0.2 and 0.30 ± 0.1 µg.h/mL-g in 242 plasma and cysts, respectively) ( Table 2) . 243 244 All infected animals involved in the efficacy study developed cysts in their abdominal cavity. Figure 5 shows 245 the weight (mean ± SD) of the cysts recovered from unmedicated control and treated mice. There were no 246 statistical differences (P> 0.05) between cysts weight recovered from the unmedicated group (10.5 ± 8.7 g) and 247
formulation in CDs impacts on the amount of drug reaching the hydatid cysts and its overall antiparasitic effect. 284
The FLBZ/R-FLBZ pattern found in cysts was similar to that observed in plasma, resulting in a cyst AUC ratio 285 Table 2 Pharmacokinetic parameters (mean ± SD) for albendazole sulphoxide (ABZSO) and albendazole sulphone (ABZSO 2 ) obtained in plasma and cyst after the oral administration of albendazole (ABZ) to mice (5 mg/kg). 
